{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:17:40Z","timestamp":1793042260045,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jpba.2024.116033","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T05:20:43Z","timestamp":1707801643000},"page":"116033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Production of antibody and development of enzyme-linked immunosorbent assay for therapeutic drug monitoring of eravacycline"],"prefix":"10.1016","volume":"242","author":[{"given":"Inna A.","family":"Galvidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia G.","family":"Moshcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury A.","family":"Surovoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel D.","family":"Sobolev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly R.","family":"Sharipov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita G.","family":"Sidorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei V.","family":"Tsarenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksim A.","family":"Burkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jpba.2024.116033_bib1","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.jpba.2024.116033_bib2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1517\/13543784.2014.965253","article-title":"Eravacycline for the treatment of intra-abdominal infections","volume":"23","author":"Bassetti","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"5","key":"10.1016\/j.jpba.2024.116033_bib3","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1128\/AAC.06187-11","article-title":"Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic","volume":"56","author":"Grossman","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2024.116033_bib4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: a review in complicated intra-abdominal infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jpba.2024.116033_bib5","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001592","article-title":"Comparative in vitro activities of omadacycline, eravacycline and tigecycline against non-ESBL-producing, ESBL-producing and carbapenem-resistant isolates of K. pneumoniae","volume":"71","author":"Mirza","year":"2022","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.jpba.2024.116033_bib6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jpba.2024.116033_bib7","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/jac\/dkab238","article-title":"Eravacycline pharmacokinetics in a critically ill patient receiving venovenous extracorporeal membrane oxygenation and continuous venovenous haemodialysis","volume":"76","author":"Igneri","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2024.116033_bib8","series-title":"Open Forum Infectious Diseases","first-page":"S521","article-title":"Pharmacokinetics (PK) of eravacycline in subjects with renal or hepatic impairment compared with healthy subjects","author":"Horn","year":"2017"},{"issue":"6","key":"10.1016\/j.jpba.2024.116033_bib9","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"10.1016\/j.jpba.2024.116033_bib10","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob. Agents Ch"},{"issue":"11","key":"10.1016\/j.jpba.2024.116033_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2024.116033_bib12","article-title":"Overview of therapeutic drug monitoring and clinical practice","author":"Fang","year":"2023","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2024.116033_bib13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper#","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.jpba.2024.116033_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114875","article-title":"Development and application of amphotericin B immunoassay for pharmacokinetic studies and therapeutic drug monitoring in critically ill patients","volume":"218","author":"Burkin","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/j.jpba.2024.116033_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/bios13030343","article-title":"Tigecycline immunodetection using developed group-specific and selective antibodies for drug monitoring purposes","volume":"13","author":"Galvidis","year":"2023","journal-title":"Biosensors"},{"key":"10.1016\/j.jpba.2024.116033_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114275","article-title":"Development of ELISA formats for polymyxin B monitoring in serum of critically ill patients","volume":"204","author":"Burkin","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2024.116033_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/bios12070493","article-title":"Immunoassay for natamycin trace screening: bread, wine and other edibles analysis","volume":"12","author":"Burkin","year":"2022","journal-title":"Biosensors"},{"issue":"13","key":"10.1016\/j.jpba.2024.116033_bib18","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1039\/C9AY02724F","article-title":"Three for the price of one! Immunodetection of three amphenicols in foodstuffs using a universal standard curve","volume":"12","author":"Galvidis","year":"2020","journal-title":"Anal. Methods"},{"issue":"51","key":"10.1016\/j.jpba.2024.116033_bib19","doi-asserted-by":"crossref","first-page":"18132","DOI":"10.1021\/jacs.8b11185","article-title":"Competitive immunoassays for the detection of small molecules using single molecule arrays","volume":"140","author":"Wang","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2024.116033_bib20","unstructured":"A. Burkin, G. Kononenko, M. Burkin, Methods of sanitary control of livestock products. I. Enzymoimmunoassay (ELISA) of tetracyclines, Sel'skokhozyaistvennaya biologiya (4) (2010) 110\u2013117."},{"issue":"2","key":"10.1016\/j.jpba.2024.116033_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/03601234.2013.726856","article-title":"Production of monoclonal antibody against doxycycline for immunoassay of seven tetracyclines in bovine muscle and milk","volume":"48","author":"Gao","year":"2013","journal-title":"J. Environ. Sci. Health Part B"},{"issue":"2","key":"10.1016\/j.jpba.2024.116033_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/jf062627s","article-title":"Preparation of anti-tetracycline antibodies and development of an indirect heterologous competitive enzyme-linked immunosorbent assay to detect residues of tetracycline in milk","volume":"55","author":"Zhang","year":"2007","journal-title":"J. Agric. Food Chem."},{"issue":"1-2","key":"10.1016\/j.jpba.2024.116033_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.aca.2003.07.003","article-title":"Investigation of the effect of hapten heterology on immunoassay sensitivity and development of an enzyme-linked immunosorbent assay for the organophosphorus insecticide fenthion","volume":"494","author":"Kim","year":"2003","journal-title":"Anal. Chim. Acta"},{"issue":"2","key":"10.1016\/j.jpba.2024.116033_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09540105.2010.533752","article-title":"Heterologous structure of coating antigen on sensitivity of ELISA for sulfamethazine: evidence from molecular similarity analysis","volume":"22","author":"Wang","year":"2011","journal-title":"Food Agric. Immunol."},{"issue":"9","key":"10.1016\/j.jpba.2024.116033_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00275-18","article-title":"Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits","volume":"62","author":"Petraitis","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.jpba.2024.116033_bib26","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00250-17","article-title":", In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T21:41:56Z","timestamp":1715290916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":26,"alternative-id":["S0731708524000736"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116033","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production of antibody and development of enzyme-linked immunosorbent assay for therapeutic drug monitoring of eravacycline","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116033"}}